



Review

Dynamic nuclear polarisation: The future of imaging in oncology?



Eva M. Serrao^{a,b,*}, Kevin M. Brindle^{a,b}

^a Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK

^b Department of Biochemistry, University of Cambridge, Cambridge, UK

ARTICLE INFO

Article history:

Received 29 December 2016

Accepted 2 January 2017

Available online 10 February 2017

Keywords:

Cancer

Metabolism

Imaging

Hyperpolarized

Pyruvate

ABSTRACT

As clinical oncology evolves with new treatment options becoming available, there is an increasing demand on anatomic imaging for the assessment of patients at different stages. Imaging with hyperpolarized ^{13}C -labelled cell substrates has the potential to become a powerful tool in many steps of clinical evaluation, offering a new metabolic metric and therefore a more personalised approach to treatment response. This article explores the metabolic basis and potential for translation of hyperpolarised pyruvate as a dynamic nuclear polarisation probe in clinical oncology.

© 2017 PBJ-Associação Porto Biomedical/Porto Biomedical Society. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

New advances in a wide range of fields from genomics to medical imaging are allowing patients to be treated and monitored more precisely and effectively and in ways that better meet their individual needs. Development of tools to truly personalise healthcare will improve our ability to predict and account for individual differences in disease diagnosis, experience, and therapy response. An increased understanding of the relationship between molecular knowledge and conventional anatomical imaging, using molecular imaging (MI), is allowing diagnostic imaging to become more specific and sensitive. The ability to non-invasively assess metabolism *in vivo* and in real time was made possible recently in humans, for the first time, through the use of dynamic nuclear polarisation (DNP) of ^{13}C -labelled metabolites, which could be detected *in vivo* using magnetic resonance spectroscopic imaging (MRSI). This article explores the metabolic basis and potential for translation of $[1-^{13}\text{C}]\text{pyruvate}$ as a DNP probe in clinical oncology. A subset of cancers is also discussed.

Metabolic changes in cancer: probing glycolysis with hyperpolarized $[1-^{13}\text{C}]\text{pyruvate}$

Metabolic reprogramming, namely increased glycolysis, is a well-recognised and highly prevalent hallmark of cancer.^{1,2} Since its first report in cancer cells under aerobic conditions, by Otto Warburg in the 1930s,^{3,4} numerous additional experimental observations have verified this same phenomenon, which was named the “Warburg effect” over the following decades.⁵ From a bioenergetic standpoint glycolysis is an inefficient process to produce energy as it makes only 2 adenosine triphosphate (ATP) molecules per glucose molecule compared to the 38 ATP molecules that complete oxidation produces. Additionally, formation and release of metabolic products, such as hydrogen ions (H^+), to the extracellular space leads to an acidic and potentially toxic environment for cells.^{6,7} At a first glance, this selection for inefficient substrate metabolism seems counterintuitive. However, a growing clinical and pre-clinical body of knowledge has revealed the relevance and advantage of this metabolic phenotype in cancer cell survival, namely in providing tumours with a powerful proliferative and invasive advantage over surrounding normal tissues.^{2,8} Increased glycolysis enables not only the generation of intermediates and cofactors essential for proliferation but also the alteration of the extra-cellular pH, specifically environmental acidosis, that facilitates invasion through destruction of adjacent normal cell populations, degradation of the extracellular matrix and promotion of angiogenesis.^{2,8}

As an almost universal cancer signature, glycolysis is a very attractive pathway to probe either pre-clinically or clinically. While positron emission tomography (PET) with computed tomography (CT) has been the metabolic imaging method most familiar to

Abbreviations: ATP, adenosine triphosphate; CT, computed tomography; DCE, dynamic contrast enhanced; DNP, dynamic nuclear polarisation; ^{18}F -FDG, ^{18}F fluorodeoxyglucose; ^{18}F -FET, ^{18}F -fluoro-ethyl-tyrosine; PET, positron emission tomography; MRS, magnetic resonance spectroscopy; MRSI, magnetic resonance spectroscopic imaging; MI, molecular imaging; PCa, pancreatic cancer; PPP, pentose phosphate pathway.

* Corresponding author.

E-mail address: Eva.Serrao@cruk.cam.ac.uk (E.M. Serrao).

<http://dx.doi.org/10.1016/j.pbj.2017.01.002>

2444-8664/© 2017 PBJ-Associação Porto Biomedical/Porto Biomedical Society. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

clinicians, other imaging techniques based on MR also exist. [$1-^{13}\text{C}$]pyruvate is the best-established metabolite in the DNP field and the only one so far that has successfully translated to the clinic.⁹ Another DNP probe, which also probes glycolysis, is ^{13}C labelled glucose which allows not only assessment of glycolytic flux but also flux into the pentose phosphate pathway (PPP).¹⁰

Pyruvate has a central role in cell metabolism. In cancer, pyruvate is mostly reversibly reduced by nicotinamide adenine dinucleotide¹¹ into lactate, in a reaction catalysed by the enzyme lactate dehydrogenase¹² or transaminated by glutamate to produce alanine in the reaction catalysed by alanine transaminase (ALT).¹³ These reactions can be probed *in vivo* and in real time using hyperpolarized [$1-^{13}\text{C}$]-pyruvate.

Basic principles of dynamic nuclear polarisation

DNP significantly (>10,000-fold) increases the signal from and therefore the sensitivity of detection of injected ^{13}C -labelled compounds *in vivo*.¹⁴ The process involves mixing ^{13}C -labelled molecules with small quantities of a stable radical, cooling the mixture to approximately 1 K in a magnetic field and irradiating the electron spins with microwave irradiation resulting in transfer of the polarisation from the fully polarised electron spins on the radical to the ^{13}C nuclei. The compound is then rapidly dissolved in hot pressurised buffer, and can then be injected into a cell suspension or an animal or a human being in a separate imaging magnet.^{15,16} The hyperpolarized signal, however, is transient and lasts *in vivo* for about 2–3 min, depending on the substrate.¹⁷

The application of this powerful approach has allowed *in vivo* imaging of metabolites and their enzymatic conversion into other species, at high temporal and relatively high spatial resolutions.^{14,18}

Translation to humans

One of the most challenging milestones for hyperpolarized substrates was achieved with [$1-^{13}\text{C}$]pyruvate with its successful translation to humans in a study in prostate cancer. This imaging proof-of-principle study showed not only the feasibility of HP [$1-^{13}\text{C}$]pyruvate as an agent for noninvasively characterising metabolic alterations in tumours but also its safety in humans.⁹ However, this technique is still in its infancy and many hurdles will need to be addressed if it is to realise a clinical role within the toolkit of existing competing clinical techniques.

Biologically, a better understanding of the relationship between the DNP image data, specific enzymatic reactions and malignancy would greatly benefit the hyperpolarized field. Further advances in our understanding of cancer biology have revealed increasing tumour heterogeneity, which significantly increases in complexity in the clinical setting. One interesting point would be to depict this heterogeneity with imaging. However, again, studies on the biological-imaging relationship are needed.

The clinical application of this technique in a daily basis will also need to be refined for reliable results to be acquired. Mirroring other metabolic imaging techniques that are already used routinely in the clinic, *i.e.* ^{18}F fluorodeoxyglucose (^{18}F -FDG) PET, improved variability of hyperpolarized [$1-^{13}\text{C}$]-pyruvate was shown when subjects were fasted.¹⁹ However this result will have to be validated in humans.

At a technical level current research has focused on improving methods for fast imaging, analyzing kinetic data, and the development of methods for increasing the hyperpolarized signal lifetime.²⁰ Improved hyperpolarizer designs, which use automated injection systems²¹ and higher field-strengths²² will improve the substrate polarisation levels at the time of injection. Further,

new methods to accelerate pyruvate polarisation can also be applied.^{23,24} Chemical derivatization to enhance tissue uptake²⁵ and prolongation of the polarisation lifetime by deuteration¹⁰ may also allow the use and development of new agents.

Potential of DNP in current clinical practice

From the very first reports HP [$1-^{13}\text{C}$]pyruvate has proved to be a very promising probe in the oncology field, with great potential to be applied in many of the clinical patient management steps.²⁶ Preclinically, hyperpolarized [$1-^{13}\text{C}$]pyruvate has been reported as an interesting screening tool for early detection and secondary screening of pancreatic cancer²⁷ (Fig. 1). In another study, [$1-^{13}\text{C}$]pyruvate detected metabolic changes prior to tumour formation.²⁸ In the clinic, increased lactate labelling was also observed in histologically confirmed areas of prostate cancer that were not identifiable by conventional ^1H -MRI measurements.⁹ The role of hyperpolarized [$1-^{13}\text{C}$]pyruvate in diagnosis and differential diagnosis between normal and cancer tissues have been widely reported, with increased lactate labelling occurring in tumour tissues.^{29,30} In the clinic, tumour grading by biopsy can sometimes be difficult given the location and accessibility of the organ of interest, *e.g.* pancreas. It is for these reasons that transfer of this technique would be interesting, as it would allow not only for more accurately targeted biopsies but also for a potential reduction in biopsy procedures under some circumstances. The few studies that have explored the role of HP [$1-^{13}\text{C}$]pyruvate in grading and prognosis in the prostate have produced promising results.^{31,32} Changes in tumour size and burden form the major part of the Response Evaluation Criteria In Solid Tumours (RECIST) criteria, which is a widely used method for assessing treatment response in clinical trials.³³ Numerous studies have demonstrated early decreases in hyperpolarized ^{13}C label exchange between injected [$1-^{13}\text{C}$]pyruvate and the endogenous lactate pool in a range of cancer models following treatment with cytotoxic chemotherapy,^{34,35} targeted drugs^{36–38} and radiotherapy^{39–41} before any tumour size change was observable.

Examples of potential clinical uses

Pancreatic cancer

Pancreatic cancer (PCa) is one of the most aggressive solid malignancies, which can potentially be cured by surgery, making early diagnosis one of the best options for improving patient survival. Imaging plays an important role in the diagnostic algorithm for PCa,⁴² with the preferred imaging studies being DCE-CT or DCE-MRI⁴³ and endoscopic ultrasonography, which may be useful in patients with equivocal CT/MRI findings.⁴⁴ The role of ^{18}F -FDG-PET remains unclear,⁴³ however its major impact has been in the detection of small metastases⁴⁵ and treatment monitoring. A recent study²⁷ has shown that imaging with hyperpolarized [$1-^{13}\text{C}$]pyruvate could make an impact in the early diagnosis of PCa in high-risk individuals, which are believed to comprise 36% of the cases of PCa.^{46–48} Imaging with hyperpolarized [$1-^{13}\text{C}$]pyruvate could also potentially play a role in other clinical challenges in PCa, including differential diagnosis of PCa from chronic pancreatitis; treatment monitoring; and early anatomic detection of tumour recurrence.

Breast cancer

DCE-MRI is the morphological reference imaging modality used in the assessment of breast cancer, with PET playing a growing role in the detection of metastatic lesions. Our increasing understanding




Fig. 1. ^{13}C chemical shift images acquired with a surface coil representing $[1-^{13}\text{C}]$ lactate, $[1-^{13}\text{C}]$ alanine and $[1-^{13}\text{C}]$ pyruvate peak intensities. Differential anatomic distribution of $[1-^{13}\text{C}]$ pyruvate, $[1-^{13}\text{C}]$ lactate and $[1-^{13}\text{C}]$ alanine in a mouse model of pancreatic cancer is demonstrated. This mouse was found to have a significant portion of high-grade pre-neoplastic lesions in the pancreas.

of the molecular complexity and heterogeneity of breast tumours⁴⁹ has led to the development of more individualised and flexible treatment strategies based on the patient's tumour type and their response to therapy. There is, therefore, an increasing need for new metrics that better characterise breast tumours, that can be used to assess their early response to treatment and that can be used to detect recurrence. Recent reports have shown that ^{18}F -FDG-PET can play a role here,^{50–52} which suggests that metabolic imaging with hyperpolarized $[1-^{13}\text{C}]$ pyruvate may also have a role, with the added advantage that the absence of ionising radiation means that it should be possible to conduct multiple imaging exams, for example to screen for the presence of recurrence.

Brain tumours

Despite advances in treatment regimens in recent years, patient survival has not improved significantly, in particular for high-grade gliomas.⁵³ Currently, DCE-MRI is the technique of choice for the clinical management of brain tumours; from initial diagnosis and biopsy-guided procedures to treatment planning and recurrence evaluation. Functional/biological characterisation of these tumours would be of value as it could help to tailor treatment at an early stage. Several studies have reported that metabolic imaging with PET can improve diagnosis. Indeed, application of ^{18}F -FDG was shown to help in the differentiation of normal, low- and high-grade gliomas^{54,55}; lesion delineation and postoperative detection of residual tumour.⁵⁶ Despite the widespread clinical application of ^{18}F -FDG, the use of amino acid tracers such as ^{11}C methionine and ^{18}F -fluoro-ethyl-tyrosine (^{18}F -FET) have been reported to have improved detection sensitivity compared with ^{18}F -FDG, particularly when assessing recurrence and differentiating it from treatment-induced changes.^{57,58} The potential advantage of using hyperpolarized ^{13}C MRI in glioma evaluation is that it may allow co-registration of detailed anatomic and functional data in a radiation free manner, which would be of particular interest in paediatric patients. This may provide a more comprehensive characterisation of tumour localisation and heterogeneity and consequently improved tumour sampling, margin delineation for radiotherapy, early detection of treatment response and post-treatment detection of recurrence.

Lymphoma

Metabolic imaging with ^{18}F -FDG-PET has long been used for staging and assessing treatment response in lymphoma patients.⁵⁹ The current recommendation is that baseline and end of treatment ^{18}F -FDG-PET images should be acquired. However, efforts are being made to include interim imaging, after either the second or fourth cycles of treatment, as a way for optimising outcome and minimising treatment toxicity. The greatest benefit of interim imaging will possibly lay in the potential to inform about “response-adapted therapy,” whereby treatment can be de-escalated in intensity in the setting of a satisfactory early response or escalated if early response

is inadequate.⁶⁰ With both approaches having shown promise in Hodgkin lymphoma,^{61–63} there are currently several ongoing clinical trials to further evaluate the value of response-adapted therapy based on findings of interim ^{18}F -FDG PET/CT scans.⁶⁴ Imaging, for example with hyperpolarized $[1-^{13}\text{C}]$ pyruvate, would have the potential to provide an improved radiation-free assessment of early treatment response, which might be of particular importance as a significant number of patients with lymphoma will be relatively young.

Future directions

Clinical oncology practice relies increasingly on anatomic imaging at different stages of patient care. DNP has the potential to provide a new dimension and understanding of tumour biological behaviour, thus allowing a more personalised patient-centric approach. Despite its proven feasibility in humans and its significant potential in clinical oncology, DNP will still have to prove itself against established and emerging clinical techniques such as PET and demonstrate its added value in clinical practice.

Author contribution

Both authors listed, have made substantial, direct, and intellectual contribution to the work, and approved it for publication.

Conflicts of interest

KB's lab has a research agreement with GE Healthcare (GEH) and holds patents on DNP technology with GEH.

Acknowledgements

Work in KMB's laboratory is supported by a Cancer Research UK Programme grant (17242) and the CRUK-EPSRC Imaging Centre in Cambridge and Manchester (16465). Clinical studies are funded by a Strategic Award from the Wellcome Trust (095962). E.M.S. was a recipient of a fellowship from the European Union Seventh Framework Programme (FP7/2007–2013) under the Marie Curie Initial Training Network *METAFLUX* (project number 264780). E.M.S. also acknowledges the educational support of the Programme for Advanced Medical Education from Calouste Gulbenkian Foundation, Champalimaud Foundation, Ministerio de Saude and Fundacao para a Ciencia e Tecnologia, Portugal.

References

- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144:646–74. <http://dx.doi.org/10.1016/j.cell.2011.02.013>.
- Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? *Nat Rev Cancer*. 2004;4:891–9. <http://dx.doi.org/10.1038/nrc1478>.
- Warburg O. On respiratory impairment in cancer cells. *Science*. 1956;124:269–70.
- Warburg O. On the origin of cancer cells. *Science*. 1956;123:309–14.

5. Semenza GL, Artemov D, Bedi A, Bhujwalla Z, Chiles K, Feldser D, et al. 'The metabolism of tumours': 70 years later. *Novartis Found Symp.* 2001;240:251–60, discussion 60–4.
6. Bhujwalla ZM, Artemov D, Ballesteros P, Cerdan S, Gillies RJ, Solaiyappan M. Combined vascular and extracellular pH imaging of solid tumors. *NMR Biomed.* 2002;15:114–9.
7. Schornack PA, Gillies RJ. Contributions of cell metabolism and H⁺ diffusion to the acidic pH of tumors. *Neoplasia.* 2003;5:135–45.
8. Dang CV. Links between metabolism and cancer. *Genes Dev.* 2012;26:877–90. <http://dx.doi.org/10.1101/gad.189365.112>.
9. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. *Sci Transl Med.* 2013;5:198ra08. <http://dx.doi.org/10.1126/scitranslmed.3006070>.
10. Rodrigues TB, Serrao EM, Kennedy BW, Hu DE, Kettunen MI, Brindle KM. Magnetic resonance imaging of tumor glycolysis using hyperpolarized ¹³C-labeled glucose. *Nat Med.* 2014;20:93–7. <http://dx.doi.org/10.1038/nm.3416>.
11. Josan S, Hurd R, Billingsley K, Senadheera L, Park JM, Yen YF, et al. Effects of isoflurane anesthesia on hyperpolarized (13)C metabolic measurements in rat brain. *Magn Reson Med.* 2013;70:1117–24. <http://dx.doi.org/10.1002/mrm.24532>.
12. Bettgowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med.* 2014;6:224ra24. <http://dx.doi.org/10.1126/scitranslmed.3007094>.
13. Golman K, Olsson LE, Axelsson O, Mansson S, Karlsson M, Petersson JS. Molecular imaging using hyperpolarized ¹³C. *Br J Radiol.* 2003;76(Spec No 2):S118–27.
14. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, et al. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. *Proc Natl Acad Sci U S A.* 2003;100:10158–63. <http://dx.doi.org/10.1073/pnas.1733835100>.
15. Kurhanewicz J, Vigneron DB, Brindle K, Chkemenev EY, Comment A, Cunningham CH, et al. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. *Neoplasia.* 2011;13:81–97.
16. Gallagher FA, Bohndiek SE, Kettunen MI, Lewis DY, Soloviev D, Brindle KM. Hyperpolarized ¹³C MRI and PET: in vivo tumor biochemistry. *J Nucl Med.* 2011;52:1333–6. <http://dx.doi.org/10.2967/jnumed.110.085258>.
17. Comment A, Merritt ME. Hyperpolarized magnetic resonance as a sensitive detector of metabolic function. *Biochemistry.* 2014;53:7333–57. <http://dx.doi.org/10.1021/bi501225t>.
18. Kurhanewicz J, Bok R, Nelson SJ, Vigneron DB. Current and potential applications of clinical ¹³C MR spectroscopy. *J Nucl Med.* 2008;49:341–4. <http://dx.doi.org/10.2967/jnumed.107.045112>.
19. Serrao EM, Rodrigues TB, Gallagher FA, Kettunen MI, Kennedy BW, Vowler SL, et al. Effects of fasting on serial measurements of hyperpolarized [1-(13)C]pyruvate metabolism in tumors. *NMR Biomed.* 2016;29:1048–55. <http://dx.doi.org/10.1002/nbm.3568>.
20. Timm KN, Kennedy BW, Brindle KM. Imaging tumor metabolism to assess disease progression and treatment response. *Clin Cancer Res.* 2016;22:5196–203. <http://dx.doi.org/10.1158/1078-0432.ccr-16-0159>.
21. Cheng T, Mishkovsky M, Bastiaansen JA, Ouari O, Hautle P, Tordo P, et al. Automated transfer and injection of hyperpolarized molecules with polarization measurement prior to in vivo NMR. *NMR Biomed.* 2013;26:1582–8. <http://dx.doi.org/10.1002/nbm.2993>.
22. Barnes AB, Markhasin E, Daviso E, Michaelis VK, Nanni EA, Jawa SK, et al. Dynamic nuclear polarization at 700 MHz/460 GHz. *J Magn Reson.* 2012;224:1–7. <http://dx.doi.org/10.1016/j.jmr.2012.08.002>.
23. Bornet A, Melzi R, Perez Linde AJ, Hautle P, van den Brandt B, Jannin S, et al. Boosting dissolution dynamic nuclear polarization by cross polarization. *J Phys Chem Lett.* 2013;4:111–4. <http://dx.doi.org/10.1021/jz301781t>.
24. Bornet A, Jannin S. Optimizing dissolution dynamic nuclear polarization. *J Magn Reson.* 2016;264:13–21. <http://dx.doi.org/10.1016/j.jmr.2015.12.007>.
25. Hurd RE, Yen YF, Mayer D, Chen A, Wilson D, Kohler S, et al. Metabolic imaging in the anesthetized rat brain using hyperpolarized [1-¹³C] pyruvate and [1-¹³C] ethyl pyruvate. *Magn Reson Med.* 2010;63:1137–43. <http://dx.doi.org/10.1002/mrm.22364>.
26. Serrao EM, Brindle KM. Potential clinical roles for metabolic imaging with hyperpolarized [1-(13)C]pyruvate. *Front Oncol.* 2016;6:59. <http://dx.doi.org/10.3389/fonc.2016.00059>.
27. Serrao EM, Kettunen MI, Rodrigues TB, Dzien P, Wright AJ, Gopinathan A, et al. MRI with hyperpolarized [1-¹³C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model. *Gut.* 2015. <http://dx.doi.org/10.1136/gutjnl-2015-310114>.
28. Hu S, Balakrishnan A, Bok RA, Anderton B, Larson PE, Nelson SJ, et al. ¹³C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. *Cell Metab.* 2011;14:131–42. <http://dx.doi.org/10.1016/j.cmet.2011.04.012>.
29. Park I, Larson PE, Zierhut ML, Hu S, Bok R, Ozawa T, et al. Hyperpolarized ¹³C magnetic resonance metabolic imaging: application to brain tumors. *Neuro Oncol.* 2010;12:133–44. <http://dx.doi.org/10.1093/neuonc/nop043>.
30. Golman K, Zandt RI, Lerche M, Pehrson R, Ardenkjaer-Larsen JH. Metabolic imaging by hyperpolarized ¹³C magnetic resonance imaging for in vivo tumor diagnosis. *Cancer Res.* 2006;66:10855–60. <http://dx.doi.org/10.1158/0008-5472.can-06-2564>.
31. Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, et al. Hyperpolarized ¹³C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. *Cancer Res.* 2008;68:8607–15. <http://dx.doi.org/10.1158/0008-5472.can-08-0749>.
32. Chen AP, Zhang V, Xu D, Veeraraghavan S, Hurd RE, Nelson SJ, et al. Serial hyperpolarized ¹³C 3D-MRSI following therapy in a mouse model of prostate cancer. *Proc Intl Soc Mag Reson Med.* 2008:888.
33. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer.* 2009;45:228–47. <http://dx.doi.org/10.1016/j.ejca.2008.10.026>.
34. Day SE, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J, et al. Detecting tumor response to treatment using hyperpolarized ¹³C magnetic resonance imaging and spectroscopy. *Nat Med.* 2007;13:1382–7. <http://dx.doi.org/10.1038/nm1650>.
35. Witney TH, Kettunen MI, Hu DE, Gallagher FA, Bohndiek SE, Napolitano R, et al. Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarized [1-¹³C]pyruvate and [1,4-¹³C]fumarate. *Br J Cancer.* 2010;103:1400–6. <http://dx.doi.org/10.1038/sj.bjc.6605945>.
36. Dafni H, Larson PE, Hu S, Yoshihara HA, Ward CS, Venkatesh HS, et al. Hyperpolarized ¹³C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor. *Cancer Res.* 2010;70:7400–10. <http://dx.doi.org/10.1158/0008-5472.can-10-0883>.
37. Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancracking M, Dafni H, et al. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized ¹³C magnetic resonance spectroscopy. *Cancer Res.* 2010;70:1296–305. <http://dx.doi.org/10.1158/0008-5472.can-09-2251>.
38. Bohndiek SE, Kettunen MI, Hu DE, Witney TH, Kennedy BW, Gallagher FA, et al. Detection of tumor response to a vascular disrupting agent by hyperpolarized ¹³C magnetic resonance spectroscopy. *Mol Cancer Ther.* 2010;9:3278–88. <http://dx.doi.org/10.1158/1535-7163.mct-10-0706>.
39. Day SE, Kettunen MI, Cherukuri MK, Mitchell JB, Lizak MJ, Morris HD, et al. Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1-¹³C]pyruvate and ¹³C magnetic resonance spectroscopic imaging. *Magn Reson Med.* 2011;65:557–63. <http://dx.doi.org/10.1002/mrm.22698>.
40. Saito K, Matsumoto S, Takakusagi Y, Matsuo M, Morris HD, Lizak MJ, et al. ¹³C-MR spectroscopic imaging with hyperpolarized [1-¹³C]pyruvate detects early response to radiotherapy in SCC tumors and HT-29 tumors. *Clin Cancer Res.* 2015. <http://dx.doi.org/10.1158/1078-0432.ccr-14-1717>.
41. Bohndiek SE, Kettunen MI, Hu DE, Brindle KM. Hyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization. *Cancer Res.* 2012;72:854–64. <http://dx.doi.org/10.1158/0008-5472.can-11-2795>.
42. Hidalgo M, Cascinu S, Kleeff J, Labianca R, Lohr JM, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. *Pancreatology.* 2014. <http://dx.doi.org/10.1016/j.pan.2014.10.001>.
43. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB III, Casper ES, et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines. *J Natl Compr Canc Netw.* 2012;10:703–13.
44. de la Santa LG, Retortillo JA, Miguel AC, Klein LM. Radiology of pancreatic neoplasms: an update. *World J Gastrointest Oncol.* 2014;6:330–43. <http://dx.doi.org/10.4251/wjgo.v6.i9.330>.
45. Low G, Panu A, Millo N, Leen E. Multimodality imaging of neoplastic and non-neoplastic solid lesions of the pancreas. *Radiographics.* 2011;31:993–1015. <http://dx.doi.org/10.1148/rq.314105731>.
46. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. *Gut.* 2013;62:339–47. <http://dx.doi.org/10.1136/gutjnl-2012-303108>.
47. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med.* 2000;343:78–85. <http://dx.doi.org/10.1056/nejm200007133430201>.
48. Lynch HT, Smyrk T, Kern SE, Hruban RH, Lightdale CJ, Lemon SJ, et al. Familial pancreatic cancer: a review. *Semin Oncol.* 1996;23:251–75.
49. Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of breast cancer heterogeneity. *Nat Rev Clin Oncol.* 2015;12:381–94. <http://dx.doi.org/10.1038/nrclinonc.2015.73>.
50. Baba S, Isoda T, Maruoka Y, Kitamura Y, Sasaki M, Yoshida T, et al. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging. *J Nucl Med.* 2014;55:736–42. <http://dx.doi.org/10.2967/jnumed.113.129395>.
51. Lim I, Noh WC, Park J, Park JA, Kim HA, Kim EK, et al. The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy. *Eur J Nucl Med Mol Imaging.* 2014;41:1852–60. <http://dx.doi.org/10.1007/s00259-014-2797-4>.
52. Miyake KK, Nakamoto Y, Kanao S, Tanaka S, Sugie T, Mikami Y, et al. Journal Club: diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer. *Am J Roentgenol.* 2014;203:272–9. <http://dx.doi.org/10.2214/ajr.13.11971>.

53. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin.* 2016;66:7–30, <http://dx.doi.org/10.3322/caac.21332>.
54. Spence AM, Muzi M, Mankoff DA, O'Sullivan SF, Link JM, Lewellen TK, et al. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. *J Nucl Med.* 2004;45:1653–9.
55. Mertens K, Acou M, Van Hauwe J, De Ruyck I, Van den Broecke C, Kalala JP, et al. Validation of 18F-FDG PET at conventional and delayed intervals for the discrimination of high-grade from low-grade gliomas: a stereotactic PET and MRI study. *Clin Nucl Med.* 2013;38:495–500, <http://dx.doi.org/10.1097/RLU.0b013e318292a753>.
56. Pirotte BJ, Lubansu A, Massager N, Wikler D, Van Bogaert P, Levivier M, et al. Clinical impact of integrating positron emission tomography during surgery in 85 children with brain tumors. *J Neurosurg Pediatr.* 2010;5:486–99, <http://dx.doi.org/10.3171/2010.1.peds09481>.
57. Takenaka S, Asano Y, Shinoda J, Nomura Y, Yonezawa S, Miwa K, et al. Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis. *Neurol Med Chir (Tokyo).* 2014;54:280–9.
58. Chen W. Clinical applications of PET in brain tumors. *J Nucl Med.* 2007;48:1468–81, <http://dx.doi.org/10.2967/jnumed.106.037689>.
59. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol.* 2014;32:3059–68, <http://dx.doi.org/10.1200/jco.2013.54.8800>.
60. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. *J Nucl Med.* 2009;50 Suppl 1:21S–30S, <http://dx.doi.org/10.2967/jnumed.108.057190>.
61. Le Roux PY, Gastinne T, Le Gouill S, Nowak E, Bodet-Milin C, Querellou S, et al. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. *Eur J Nucl Med Mol Imaging.* 2011;38:1064–71, <http://dx.doi.org/10.1007/s00259-011-1741-0>.
62. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. *Lancet.* 2012;379:1791–9, [http://dx.doi.org/10.1016/s0140-6736\(11\)61940-5](http://dx.doi.org/10.1016/s0140-6736(11)61940-5).
63. Avigdor A, Bulvik S, Levi I, Dann EJ, Shemtov N, Perez-Avraham G, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. *Ann Oncol.* 2010;21:126–32, <http://dx.doi.org/10.1093/annonc/mdp271>.
64. Kostakoglu L, Gallamini A. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift? *J Nucl Med.* 2013;54:1082–93, <http://dx.doi.org/10.2967/jnumed.113.120451>.